World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Linitis Plastica and colonic obstruction: A comprehensive review of clinical challenges and outcomes

Ali Mohtashami *, Jonathan Hew, Vishak Senthil and Justin Evans

Department of Colorectal Surgery, Royal North Shore Hospital, Sydney, Australia.

World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 446-456

Publication history: Received on 08 January 2025; revised on 15 February 2025; accepted on 18 February 2025

Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0199

Abstract

Background: *Linitis Plastica* (LP) is a rare and highly aggressive form of gastric cancer characterized by diffuse infiltration of the stomach wall, leading to thickening and fibrosis. Due to its insidious onset and lack of early-specific symptoms, LP is often diagnosed at advanced stages, resulting in poor prognosis and limited therapeutic options. This review aims to provide a comprehensive overview of the clinical features, pathophysiology, diagnosis, and treatment options for LP, with a focus on the challenges posed by its association with colonic obstruction.

Methods: This review synthesizes available literature on LP, including studies on its clinical features, diagnostic approaches, treatment options, and emerging therapies. The review also examines advancements in early detection techniques, such as liquid biopsy and imaging modalities, and the role of multidisciplinary care in managing advanced disease.

Results: Early detection remains a major challenge in LP, as most cases are diagnosed after the disease has progressed to advanced stages. Standard treatments, including chemotherapy and surgery, have limited efficacy in improving survival due to the tumor's diffuse nature and early metastasis. Emerging therapies, such as targeted treatments, immunotherapy, and biomarkers, offer promising avenues for improving outcomes, but further research is needed to fully understand their role in LP management. Advancements in early detection techniques could help identify LP at earlier, more treatable stages. Multidisciplinary approaches integrating chemotherapy, surgery, and symptomatic relief are essential to improving quality of life for affected patients.

Conclusions: The review concludes that future research should focus on personalized treatment strategies, including molecular profiling and immune-based therapies, to offer better treatment options for this aggressive and often fatal condition.

Keywords: *Linitis Plastica*; Colonic Obstruction; Gastric Cancer; Diffuse Gastric Cancer; Chemotherapy; Targeted Therapy; Immunotherapy; HER2-Positive Gastric Cancer; Colorectal Metastasis; Palliative Care

1. Introduction

Linitis Plastica (LP) is a rare and aggressive form of gastric cancer, often referred to as "leather bottle stomach" due to its characteristic thickening and rigidity of the stomach wall (1). Unlike the more common forms of gastric adenocarcinoma, LP is notable for its diffuse infiltration of cancerous cells, leading to significant fibrosis and muscularis propria involvement (1). This aggressive growth pattern often results in a stomach that becomes stiff and unable to expand, which leads to the hallmark clinical symptoms of early satiety, weight loss, and vague abdominal discomfort.

* Corresponding author: Ali Mohtashami

The clinical presentation of LP can be insidious, with many patients presenting at an advanced stage, contributing to a poor prognosis (1).

LP is most commonly diagnosed in the later stages of disease when the cancer has already spread beyond the gastric wall. While the stomach is the primary site of involvement, LP can metastasize to surrounding structures, including the peritoneum, liver, and, in some cases, the colon (2). One of the more challenging complications of LP is its potential to cause colonic obstruction, a serious condition that requires immediate clinical attention. Although colonic obstruction as a consequence of LP is a relatively rare phenomenon, its occurrence significantly complicates the diagnosis and management of affected patients (2). The obstruction can result from direct invasion of the colon, peritoneal metastasis leading to adhesions, or mass effects that compress the colon (2).

Understanding the connection between LP and colonic obstruction is crucial for clinicians, as it demands a nuanced diagnostic approach and comprehensive management plan (3). Diagnosing both LP and colonic obstruction involves sophisticated imaging techniques, endoscopy, and often exploratory surgery, given that LP's diffuse nature can sometimes obscure clear radiological and endoscopic findings (3). Moreover, the treatment of colonic obstruction in the context of LP requires a multidisciplinary approach, including oncological management to address the underlying gastric malignancy and surgical intervention to relieve the obstruction (3).

This review aims to provide a comprehensive analysis of the pathophysiology, clinical presentation, diagnostic challenges, and treatment strategies related to *Linitis Plastica* and its potential to cause colonic obstruction. We will explore the mechanisms by which LP can lead to bowel obstruction, delve into current management strategies, and highlight key clinical studies that provide insight into the prognosis and outcomes for affected patients.

If you'd like, I can help you search for specific studies or review articles to cite, or I can help format specific citations once you have your sources. Let me know how you'd like to proceed!

2. Pathophysiology of *Linitis Plastica*

Linitis Plastica (LP) is a distinctive subtype of gastric adenocarcinoma, characterized by its diffuse infiltration of the gastric wall, which leads to thickening, fibrosis, and a rigid, non-expandable stomach. This aggressive form of cancer is often referred to as "leather bottle stomach" due to its unique appearance on imaging studies, where the stomach appears contracted and stiff, resembling a leather bottle (4). Unlike other forms of gastric cancer, LP tends to grow without forming a discrete tumor mass, which makes it difficult to detect in the early stages (4).

Histologically, LP is characterized by the infiltration of the stomach's mucosa and submucosa by signet-ring cells, which are typically the hallmark of gastric adenocarcinoma (4). These cells are named for their appearance: large cytoplasmic vacuoles that push the nucleus to one side, resembling a signet ring. The invasion of these cells leads to extensive desmoplastic reactions, causing the fibrous thickening of the gastric wall and a loss of normal gastric architecture. As the disease progresses, the affected portion of the stomach becomes rigid, and its ability to expand and contract during digestion is compromised (4). This leads to symptoms such as early satiety, weight loss, and abdominal discomfort, which are common in LP patients (4).

The spread of LP can occur through several mechanisms, including direct invasion of adjacent tissues, lymphatic dissemination, and hematogenous spread (4). Direct extension may involve adjacent organs such as the liver, pancreas, or colon. Notably, peritoneal involvement is common in LP, as the tumor spreads through the peritoneum, leading to the formation of peritoneal implants and adhesions (4). This peritoneal spread can contribute to the development of colonic obstruction, either through the formation of fibrous bands or direct tumor infiltration that encroaches upon or compresses the colon (3,4).

The molecular pathogenesis of LP is complex, with several key factors contributing to its aggressive nature. Genetic mutations in tumor suppressor genes such as TP53, E-cadherin (CDH1), and ARID1A have been identified as crucial drivers of LP (5) The loss of E-cadherin, a protein responsible for maintaining cell adhesion, is particularly important in LP. Its loss leads to the disruption of cellular architecture, facilitating the invasion of cancer cells into the surrounding tissues and promoting metastasis (5). Studies also suggest that mutations in KRAS and PIK3CA pathways, which regulate cell proliferation and survival, may contribute to LP's aggressive behavior (5).

Recent studies have highlighted the role of the tumor microenvironment in the pathogenesis of LP. The fibrotic tissue that forms in response to cancerous invasion is not only a result of cancer cell proliferation but also of the host's inflammatory response. The interaction between cancer cells and stromal cells leads to the secretion of cytokines and

growth factors such as TGF-β, which promotes fibrosis and enhances tumor growth (6). This desmoplastic reaction contributes to the rigidity of the stomach wall and may affect neighboring organs, including the colon, further complicating diagnosis and treatment.

Overall, the pathophysiology of LP is characterized by an aggressive, diffuse cancer growth pattern that leads to gastric wall thickening, fibrosis, and invasion of adjacent structures, including the colon. The molecular and histological features of LP, combined with its tendency to spread via peritoneal seeding, highlight the complexity of diagnosing and treating this rare form of gastric cancer. Understanding these underlying mechanisms is crucial for improving diagnostic strategies and treatment options for patients with LP and associated complications, including colonic obstruction.

2.1. Etiology and Risk Factors

The exact cause of *Linitis Plastica* (LP) remains unclear, but multiple genetic, environmental, and lifestyle factors have been identified as contributing to its development. Understanding the etiology and risk factors associated with LP is crucial for identifying at-risk populations and for developing preventive and therapeutic strategies.

2.1.1. Genetic Factors

Genetics play a significant role in the development of LP, particularly in familial forms of gastric cancer. One of the most well-known genetic mutations associated with LP is in the CDH1 gene, which encodes the E-cadherin protein. E-cadherin is a cell adhesion molecule that maintains cellular architecture and integrity. The loss or mutation of E-cadherin has been implicated in the development of diffuse gastric cancer, including LP, as it promotes the invasive behavior of cancer cells (7). Hereditary diffuse gastric cancer (HDGC) syndrome, which is associated with mutations in the CDH1 gene, is a key hereditary risk factor for LP. Individuals carrying this mutation have an increased lifetime risk of developing LP and other forms of gastric cancer (7).

In addition to the CDH1 mutation, other genetic alterations, such as mutations in the TP53 tumor suppressor gene, ARID1A, and PIK3CA pathways, have been identified in LP patients. These mutations contribute to the uncontrolled proliferation and survival of cancer cells, further facilitating the progression of LP (7). Studies have shown that these genetic mutations can also influence the tumor's response to therapy, affecting prognosis and treatment decisions (7).

2.1.2. Environmental and Lifestyle Factors

Environmental and lifestyle factors also contribute to the risk of developing LP. Chronic infection with Helicobacter pylori (H. pylori), a bacterium known to cause chronic gastritis, has been linked to an increased risk of gastric cancer. H. pylori infection induces an inflammatory response that can lead to gastric mucosal damage and dysplasia, eventually resulting in cancer (8). The link between H. pylori and LP specifically is still under investigation, but several studies have suggested that long-term infection with this bacterium may increase the risk of diffuse gastric cancer (8).

Dietary factors also play a role in gastric cancer risk. Diets high in salt, preserved foods, and smoked meats have been implicated in increasing the risk of gastric cancer, particularly in populations with a high prevalence of LP (9). These dietary factors may lead to mucosal damage or alter the gut microbiome, which can promote carcinogenesis. In contrast, a diet rich in fruits, vegetables, and fiber has been associated with a lower risk of gastric cancer, including LP (9).

2.2. Age and Gender

Age and gender are also important risk factors for LP. LP is most commonly diagnosed in individuals between the ages of 40 and 60 years, with a peak incidence in the fifth decade of life (9). The incidence of LP is relatively equal between men and women, although some studies have shown a slight male predominance (9).

2.3. Family History and Hereditary Syndromes

A positive family history of gastric cancer, particularly in first-degree relatives, is a significant risk factor for developing LP. In addition to HDGC, other genetic syndromes have been linked to an increased risk of gastric cancer. For example, Li-Fraumeni syndrome, caused by mutations in the TP53 gene, and Peutz-Jeghers syndrome, which is characterized by mutations in the STK11 gene, both increase the risk of various cancers, including gastric malignancies (10). However, familial aggregation of LP remains relatively rare compared to other forms of gastric cancer, which makes identifying at-risk families more challenging.

2.3.1. Additional Risk Factors

Other risk factors that have been implicated in gastric cancer, including LP, include smoking, alcohol consumption, and gastric surgeries. Smoking and heavy alcohol use are well-known carcinogens that can damage the gastric mucosa and increase the risk of gastric cancer (10). Additionally, patients who have undergone partial gastrectomies or other types of gastric surgery for benign conditions are at an elevated risk for developing gastric cancer, including LP (10). The exact mechanisms by which prior gastric surgery increases cancer risk are still unclear but may involve changes in gastric anatomy or alterations in gastric pH and bacterial flora.

3. Geographic and Ethnic Variations

Geographic and ethnic differences in the incidence of LP and gastric cancer are also significant. LP is more common in regions with a high incidence of gastric cancer, such as parts of East Asia (particularly Japan and Korea), Eastern Europe, and South America (11). These regions tend to have higher rates of H. pylori infection and dietary patterns associated with gastric cancer, which likely contributes to the increased prevalence of LP in these areas. Ethnically, LP has been reported more frequently in individuals of Japanese and South American descent, although it is not exclusive to any particular ethnic group (11).

4. Clinical Features and Diagnosis

Linitis Plastica (LP) is often diagnosed at an advanced stage due to its insidious onset and lack of specific symptoms in the early phases of the disease. The clinical presentation of LP can vary, but common symptoms often overlap with those of other gastrointestinal disorders, leading to challenges in early diagnosis. Recognizing the hallmark signs of LP and distinguishing it from other forms of gastric cancer is critical for effective management.

4.1. Clinical Features

The most common clinical features of LP include early satiety, weight loss, abdominal pain, and nausea. Early satiety occurs due to the reduced gastric capacity and impaired motility caused by the fibrosis and rigid thickening of the stomach wall (12). Patients often report feeling full after consuming only small amounts of food. Weight loss is a common symptom, typically a result of anorexia, reduced food intake, and increased metabolic demands associated with the cancer's growth (12).

Unlike other types of gastric cancer, LP rarely presents with a palpable mass or obstructive symptoms in the early stages, which makes diagnosis more challenging. When the disease progresses, however, symptoms such as vomiting, dysphagia, and gastric outlet obstruction may become apparent (12). These symptoms are often related to the fibrotic changes in the gastric wall, which hinder the normal digestive process. In more advanced cases, patients may also experience anemia due to chronic bleeding from the tumor or gastrointestinal perforation (12).

Due to its diffuse growth pattern, LP is typically diagnosed later in its course. It is frequently associated with peritoneal metastasis, which can lead to additional symptoms such as ascites and abdominal distension. Peritoneal implants can also cause intestinal obstruction, including colonic obstruction, by compressing or infiltrating the colon (12).

4.2. Diagnostic Approaches

The diagnosis of LP often involves a combination of clinical evaluation, imaging studies, endoscopy, and histopathological examination. Given the absence of a distinct mass and the diffuse nature of the disease, radiologic imaging plays a key role in identifying LP.

- **Endoscopy**: Upper gastrointestinal (GI) endoscopy is usually the first step in the diagnostic workup when LP is suspected. Although LP can present with a normal-appearing mucosa in its early stages, endoscopic biopsy is essential for histological diagnosis. The hallmark feature on endoscopy is the stiffened, non-distensible stomach with a "leather bottle" appearance (13). However, early-stage LP may appear as subtle mucosal thickening without obvious mass formation, making it difficult to diagnose through endoscopy alone (13).
- **Imaging Studies**: **Computed tomography (CT)** and **magnetic resonance imaging (MRI)** are invaluable in evaluating the extent of the disease and identifying peritoneal or distant metastasis. On CT imaging, LP typically appears as a thickened, rigid gastric wall without a discrete mass, which is characteristic of the diffuse infiltrative growth pattern of the disease (13). These imaging techniques can also detect complications such as gastric outlet obstruction, peritoneal metastasis, and, in some cases, colonic obstruction caused by the direct invasion of LP into the adjacent colon (13).

Endoscopic ultrasound (EUS) may be used to assess the depth of gastric wall involvement and to detect any nodal or peritoneal metastases that might not be apparent on CT or MRI (13). EUS is particularly helpful in determining the staging of LP, especially when the tumor involves the deeper layers of the gastric wall (13).

- **Histopathological Examination**: A definitive diagnosis of LP requires histological examination of gastric biopsy samples. LP is characterized by signet-ring cells in the tumor tissue, which is a key feature differentiating it from other forms of gastric cancer (14). These cells, which have a large vacuole that pushes the nucleus to the periphery, are critical in confirming the diagnosis. Immunohistochemical studies often reveal loss of E-cadherin expression, further supporting the diagnosis of LP (14). The histopathological findings of LP include diffuse infiltration of the gastric wall with minimal mucosal involvement, making it challenging to detect in routine biopsy samples (14).
- **Laparoscopy and Biopsy**: In cases where other diagnostic methods are inconclusive, laparoscopy may be performed to evaluate the peritoneal cavity and obtain biopsies from suspected peritoneal implants or lymph nodes. Laparoscopy is particularly useful in detecting peritoneal metastasis, which is common in LP, and can provide important prognostic information (15).

4.3. Challenges in Diagnosis

The diagnosis of LP can be delayed or missed due to its subtle and often nonspecific clinical presentation. The lack of a distinct mass and the non-specific nature of early symptoms can result in LP being misdiagnosed as a more common gastrointestinal disorder, such as peptic ulcer disease or functional dyspepsia (15). Additionally, the insidious onset of symptoms and the aggressive, diffuse nature of LP often lead to diagnosis at an advanced stage, which negatively impacts the prognosis.

In cases where colonic obstruction is present, the presence of gastrointestinal symptoms and radiologic evidence of bowel involvement, including thickened bowel walls or compressive mass effects, can help differentiate LP from other causes of colonic obstruction (15). However, since colonic obstruction is a relatively uncommon complication of LP, it is often overlooked in initial evaluations, leading to delayed treatment.

4.4. Differential Diagnosis

Several other conditions must be considered when diagnosing LP, including gastric lymphoma, other forms of gastric adenocarcinoma, and gastrointestinal stromal tumors (GISTs). Gastric lymphoma may present with a similar infiltrative growth pattern, but endoscopic biopsy and immunohistochemistry can help differentiate between these entities. GISTs, while rare, can mimic LP's symptoms and radiologic appearance, but they typically show a different immunohistochemical profile and behavior (15).

5. Management and Treatment

The management of *Linitis Plastica* (LP) remains challenging due to the diffuse nature of the disease, its advanced presentation at diagnosis, and the lack of effective treatment modalities. LP is an aggressive form of gastric cancer, often diagnosed at an advanced stage when curative treatment is no longer possible. The treatment strategy for LP involves a multimodal approach, including surgery, chemotherapy, and radiation therapy. However, the prognosis is generally poor, and treatment decisions should be tailored to the individual patient based on disease stage, performance status, and overall health.

5.1. Surgical Treatment

Surgery remains the cornerstone of treatment for localized LP. However, due to the diffuse infiltration of the gastric wall, surgical intervention is challenging, and the disease is often diagnosed too late for curative surgery. Total gastrectomy is typically the recommended procedure for patients with resectable LP. In cases where the disease has not spread beyond the stomach, total gastrectomy can offer the potential for long-term survival, though this is rare.

The surgery involves the complete removal of the stomach, which can be curative if the tumor is confined to the gastric wall and not associated with peritoneal or distant metastasis. However, even with complete resection, the prognosis remains poor due to the high rate of recurrence (16). In advanced cases with peritoneal metastasis, surgery is generally palliative, aimed at alleviating symptoms such as gastric outlet obstruction or bleeding (16).

Lymphadenectomy is an important part of the surgical management of LP, as regional lymph node involvement is common. The extent of lymph node dissection depends on the stage of the disease and the surgeon’s assessment (16).

While surgery can help alleviate symptoms and improve quality of life, it is not curative in advanced cases, and adjuvant therapy is typically required to control disease progression.

5.2. Chemotherapy

Given the aggressive and metastatic nature of LP, chemotherapy is a critical component of the treatment regimen, particularly in patients with advanced disease or those who are not candidates for surgery. The role of chemotherapy in LP is based on the same principles as for other forms of gastric cancer, though it is often less effective in LP due to its diffuse nature and the lack of a distinct tumor mass.

The standard chemotherapy regimen for gastric cancer often includes a combination of platinum-based agents (such as cisplatin or oxaliplatin) and fluoropyrimidines (such as 5-fluorouracil [5-FU] or capecitabine) (17). More recently, capecitabine and oxaliplatin (XELOX) has become a preferred regimen due to its more convenient oral administration and similar efficacy to 5-FU-based regimens (17). Trastuzumab, a monoclonal antibody targeting HER2, is used for HER2-positive gastric cancer, which can be found in a subset of LP patients (17).

Chemotherapy is typically used in the neoadjuvant (pre-surgery) or adjuvant (post-surgery) settings, or in cases where surgery is not feasible, to control disease progression and improve survival rates. Despite the aggressive nature of LP, chemotherapy can improve overall survival, particularly in patients with resectable tumors, but it remains less effective in those with advanced or metastatic disease (17).

In addition to standard chemotherapy, targeted therapies and immunotherapy are areas of growing interest in the treatment of LP. Drugs such as ramucirumab (a VEGFR2 inhibitor) and pembrolizumab (a PD-1 inhibitor) have shown promise in treating advanced gastric cancer, including LP (17). These therapies may offer improved outcomes for patients who do not respond to conventional chemotherapy.

5.3. Radiotherapy

Radiation therapy is generally not a first-line treatment for LP but may be used as a palliative measure for controlling symptoms such as bleeding, pain, and obstruction, particularly in patients with peritoneal involvement (17). It may also be used to treat colonic obstruction if LP has spread to involve the colon.

Preoperative radiation therapy can sometimes be used in the neoadjuvant setting to reduce tumor size and make surgery more feasible, but this approach is not standard practice due to the poor response of LP to radiation (17). Radiotherapy is more commonly employed in cases of locally advanced disease or for symptom management in palliative care settings, where it can help control the growth of the tumor and relieve symptoms without the need for more invasive procedures (17).

5.4. Palliative Care

Given the poor prognosis associated with LP, particularly in advanced stages, palliative care plays a crucial role in improving the quality of life of patients. Palliative treatments aim to alleviate symptoms such as pain, nausea, vomiting, and obstruction, thereby enhancing the patient's comfort during the terminal phase of the disease.

For patients with gastrointestinal obstruction (including colonic obstruction), the management includes stent placement or gastrostomy tube placement to ensure nutritional intake and alleviate symptoms of obstruction. For those experiencing significant pain, the use of opioid analgesics and antiemetic therapy can significantly improve quality of life (18). Psychosocial support is also essential to help patients and their families cope with the emotional and psychological burden of this terminal diagnosis.

6. Prognosis and Future Directions

The prognosis for LP remains poor, with most patients presenting with advanced disease at the time of diagnosis. The 5-year survival rate for patients with LP is typically less than 10%, reflecting the aggressive nature of the disease and the challenges in treatment (19). Even with surgical intervention, the rate of recurrence is high due to the diffuse spread of the cancer and its tendency to metastasize early.

Emerging treatments such as targeted therapies (e.g., HER2-targeted agents) and immunotherapy (e.g., immune checkpoint inhibitors) offer hope for improving outcomes, especially in patients who are not responsive to conventional chemotherapy. The identification of biomarkers that predict response to specific treatments is also an area of ongoing research, which could lead to more personalized and effective therapies for LP patients in the future (19).

6.1. Multidisciplinary Approach

The management of LP requires a multidisciplinary team approach, involving oncologists, surgeons, radiologists, pathologists, and palliative care specialists to optimize treatment and support the patient throughout their disease course. Coordination between specialists ensures comprehensive care, balancing aggressive treatment options with supportive care measures to address both the physical and emotional needs of patients with LP.

7. Prognosis and Future Directions

7.1. Prognosis of *Linitis Plastica*

Linitis Plastica (LP) is one of the most aggressive and challenging forms of gastric cancer, with a poor overall prognosis. The diffuse nature of the disease, which leads to thickening and fibrosis of the gastric wall, makes it difficult to detect in its early stages. By the time it is diagnosed, LP has often spread beyond the stomach, resulting in a low survival rate and a high risk of recurrence.

The 5-year survival rate for LP is generally below 10%, reflecting its aggressive biological behavior and the difficulty in achieving curative treatment (20). While surgery may provide a chance for prolonged survival in patients with localized disease, the majority of patients present with advanced disease at diagnosis, at which point curative surgery is no longer an option. In these cases, chemotherapy and palliative care become the primary treatment modalities.

A major factor influencing prognosis is the presence of peritoneal metastasis and lymphatic spread. In LP, the tumor cells infiltrate the stomach wall and often spread to surrounding tissues, including the peritoneum. This leads to ascites, intestinal obstruction, and further systemic metastasis, all of which contribute to a poor outcome. Furthermore, LP is less likely to present with a mass or distinct tumor, making it harder to diagnose early, thus limiting the potential for effective treatment (20).

Histological features also play a critical role in the prognosis of LP. The presence of signet-ring cells in the biopsy samples is a hallmark of LP and is associated with a more aggressive disease course (20). Moreover, the loss of E-cadherin expression, a key protein involved in cell adhesion, is commonly observed in LP and correlates with tumor progression and poor prognosis (20).

7.2. Factors Influencing Prognosis

Several factors can influence the prognosis of LP, including:

- **Tumor Stage at Diagnosis**: Early-stage LP confined to the stomach wall may be amenable to surgery, with potentially better outcomes. However, most cases present with advanced disease, including peritoneal and lymphatic metastasis, which significantly worsen prognosis (20).
- **Age and Performance Status**: Younger patients with good performance status may benefit from aggressive treatment strategies such as chemotherapy and surgery, leading to improved survival compared to elderly patients or those with poor overall health (20).
- **Histopathological Features**: As previously mentioned, the presence of signet-ring cells and loss of E-cadherin expression are associated with a more aggressive course of the disease and a worse prognosis. Other histological characteristics, such as the extent of invasion into surrounding tissues, may also influence survival (20).
- **Metastatic Spread**: The extent of metastatic spread to the peritoneum, lymph nodes, and distant organs plays a key role in prognosis. The earlier metastasis occurs, the poorer the prognosis. Notably, peritoneal carcinomatosis, which is common in LP, is associated with significant morbidity and mortality, with limited treatment options available (20).

7.3. Future Directions in Treatment and Research

Given the dismal prognosis of LP, advances in treatment and a better understanding of the disease's molecular mechanisms are urgently needed. Currently, the management of LP largely relies on chemotherapy, surgery, and

palliative care. However, due to the aggressive nature of LP, these treatments are often insufficient for long-term survival, highlighting the need for innovative therapeutic strategies.

7.4. Molecular Targeted Therapies

One area of significant research is the development of molecularly targeted therapies that can address specific genetic mutations and alterations present in LP. Targeting the HER2/neu receptor, for instance, has shown promise in gastric cancer, including LP, particularly in HER2-positive cases. Trastuzumab, an anti-HER2 monoclonal antibody, has been successfully used in combination with chemotherapy for HER2-positive gastric cancer, and ongoing clinical trials are exploring its potential in LP (18-20).

The epidermal growth factor receptor (EGFR) pathway is another potential target for therapy, as it plays a crucial role in cancer cell proliferation and survival. Drugs that inhibit EGFR, such as cetuximab, are being studied for their effectiveness in gastric cancer, including LP (20).

7.5. Immunotherapy

Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab (anti-PD-1) and nivolumab (anti-PD-1), has emerged as an exciting avenue for treating various cancers, including gastric cancer. These therapies work by reactivating the body's immune system to recognize and destroy cancer cells. Early-phase clinical trials have shown promise for the use of immune checkpoint inhibitors in advanced gastric cancer, and ongoing studies are evaluating their potential benefit for LP patients (19,20).

Furthermore, CAR-T (Chimeric Antigen Receptor T-cell) therapy is an area of growing interest in the treatment of various malignancies, and its application in gastric cancer, particularly in those with high expression of specific antigens, is an exciting area for future research (20). However, immunotherapy's role in LP specifically remains under investigation, and more clinical trials are needed to establish its efficacy.

7.6. Liquid Biopsy and Biomarkers

A major challenge in the management of LP is the lack of early diagnostic methods and biomarkers that can predict treatment response. Recent advancements in liquid biopsy, which involves the analysis of tumor-derived DNA or RNA from blood samples, hold potential for detecting circulating tumor DNA (ctDNA) or microsatellite instability (MSI) in LP patients (20). This could enable earlier diagnosis, monitoring of treatment response, and detection of minimal residual disease or recurrence.

Additionally, genetic profiling and molecular biomarkers could allow for the development of personalized treatment approaches based on the specific mutations or molecular alterations present in each patient's tumor. For example, microsatellite instability (MSI) or mismatch repair deficiency (dMMR) are potential biomarkers that could guide the use of specific therapies, such as immune checkpoint inhibitors, in a subset of LP patients (20).

7.7. Early Detection and Screening

Early detection remains a key challenge in improving the prognosis of LP. As current diagnostic methods often detect the disease at advanced stages, efforts to develop better screening techniques and biomarkers for early detection are essential. Endoscopic screening and the use of advanced imaging techniques, such as endoscopic ultrasound (EUS) or CT imaging, may help in identifying early gastric involvement or pre-cancerous lesions, allowing for more effective intervention before the disease becomes advanced (20).

While the prognosis for patients with *Linitis Plastica* remains poor, advances in the understanding of the molecular and genetic basis of the disease offer hope for more effective treatments in the future. Targeted therapies, immunotherapy, and the use of biomarkers for early detection and personalized treatment hold significant promise for improving outcomes in LP patients. However, these approaches require further investigation through clinical trials and research into the specific molecular pathways involved in LP's pathogenesis. Ultimately, a more individualized approach to treatment, coupled with earlier detection, may offer the best opportunity for improving survival and quality of life for patients with this devastating disease.

8. Discussion

Linitis Plastica (LP) is a rare and highly aggressive subtype of gastric cancer characterized by diffuse infiltration of the stomach wall. Its presentation is typically advanced, with patients often exhibiting widespread metastasis by the time

of diagnosis. This aggressive clinical course, combined with a lack of early diagnostic markers, results in a poor prognosis for LP patients, with low overall survival rates. Despite the challenges associated with managing LP, there have been some significant advances in our understanding of the disease and its treatment.

8.1. Current Treatment Landscape

The standard treatment for LP remains surgery, which is most effective when the disease is localized to the stomach. However, due to the diffuse nature of LP, surgical intervention is often not feasible in many cases, and the majority of patients present with advanced disease. In these patients, chemotherapy plays a central role in treatment, although it is only palliative in most cases. The use of platinum-based regimens such as cisplatin or oxaliplatin, in combination with fluoropyrimidines like capecitabine, represents the backbone of chemotherapy in gastric cancer, including LP (21).

Targeted therapies, especially those aimed at the HER2 receptor, are also showing promise for certain subsets of LP patients. Trastuzumab, a monoclonal antibody targeting HER2, has been shown to improve survival in HER2-positive gastric cancer and is increasingly being incorporated into treatment regimens for LP with HER2 overexpression (21). Despite these advancements, however, LP remains a therapeutic challenge due to its ability to metastasize early and resist treatment.

8.2. Challenges in Management

One of the major hurdles in managing LP is the lack of early detection methods. By the time LP is diagnosed, it has usually reached an advanced stage, limiting the effectiveness of curative treatments. Moreover, the absence of specific symptoms in the early phases of the disease further complicates diagnosis. Endoscopy, CT scans, and ultrasound may detect disease in its later stages, but there is a need for more effective screening techniques that can identify patients at risk for LP earlier in the disease course (21).

Additionally, the heterogeneous nature of LP poses significant challenges in treatment response. Not all patients with LP respond equally to standard chemotherapy regimens, and the development of predictive biomarkers is crucial for tailoring therapies to the individual patient. The identification of molecular markers, such as those related to microsatellite instability (MSI) or tumor mutational burden (TMB), could enable more targeted treatments that are better suited to specific genetic profiles (22).

8.3. Emerging Therapies and Future Directions

The future of LP treatment lies in the continued exploration of targeted therapies, immunotherapies, and the development of personalized treatment regimens. Targeting molecular pathways such as EGFR, HER2, and VEGF holds promise for improving outcomes for LP patients. Drugs like ramucirumab (VEGF receptor 2 inhibitor) and trastuzumab have demonstrated clinical efficacy in gastric cancer and are currently being explored in LP through clinical trials (22).

Immunotherapy also offers new hope for LP patients, particularly with the advent of immune checkpoint inhibitors like pembrolizumab and nivolumab. These therapies work by blocking the PD-1/PD-L1 interaction, which allows the immune system to recognize and attack tumor cells. Recent studies have demonstrated promising results for checkpoint inhibitors in **gastric cancer** (22), and ongoing clinical trials are investigating their potential in LP as well. However, the efficacy of immunotherapy in LP, particularly when compared to more conventional treatments, is still under evaluation and requires further investigation.

Additionally, liquid biopsy and other advanced molecular diagnostic tools are paving the way for more accurate, non-invasive methods of detecting early-stage LP and monitoring disease progression. The ability to detect tumor DNA or mutations in the blood could significantly improve early diagnosis, enabling clinicians to intervene at a more treatable stage (22).

8.4. Palliative Care

Given the poor prognosis associated with LP, palliative care is a critical component of treatment for patients with advanced disease. Palliative approaches, including pain management, nutrition support, and symptom control, are essential to improve the quality of life for patients as they navigate the advanced stages of LP. For instance, gastrostomy tube placement and stent insertion can help manage gastrointestinal obstruction, a common complication in advanced LP (18).

Furthermore, psychosocial support plays a key role in the overall well-being of patients and their families. Addressing the emotional and psychological needs of patients with advanced LP is crucial in providing comprehensive care.

Palliative care teams should be integrated early in the management of LP to ensure that patients receive the necessary physical, emotional, and spiritual support (18).

9. Conclusion

While *Linitis Plastica* remains one of the most challenging forms of gastric cancer to treat, ongoing research into its molecular underpinnings, as well as the development of new therapeutic options such as immunotherapy and targeted therapies, offers hope for improving patient outcomes. Advances in biomarker identification and early detection methods also hold the potential to catch the disease earlier, when treatment options may be more effective. Despite these advances, the prognosis for LP remains poor, and a multidisciplinary, individualized approach to treatment, along with continued research, is essential to improve both survival and quality of life for patients.

Further clinical trials are needed to assess the effectiveness of newer treatments and to identify the most promising strategies for managing LP. The future of LP treatment lies in the development of personalized, precision medicine strategies that account for the tumor's genetic and molecular profile, as well as the patient's individual needs. With continued research and collaboration, the hope is that *Linitis Plastica* can become a more manageable disease, with better treatment outcomes and improved survival rates for patients.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: *Linitis Plastica*. World journal of surgical oncology. 2017 Dec;15:1-4.

[2] Franke AJ, Iqbal A, Starr JS, Nair RM, George Jr TJ. Management of malignant bowel obstruction associated with GI cancers. Journal of oncology practice. 2017 Jul;13(7):426-34.

[3] Rao TR, Hambrick E, Abcarian H, Salgia K, Recant WM. Colorectal *Linitis Plastica*. Diseases of the Colon & Rectum. 1982 Apr;25:239-44.

[4] Mastoraki A, Papanikolaou IS, Sakorafas G, Safioleas M. Facing the challenge of managing *Linitis Plastica*--review of the literature. Hepatogastroenterology. 2009 Nov 1;56(96):1773-8.

[5] Liu Z, Hong LL, Zheng JS, Ling ZN, Zhang ZL, Qi YN, Zhang XY, Zhu TY, Wang JL, Han J, Chen XL. Comprehensive transcriptomic profiling and mutational landscape of primary gastric *Linitis Plastica*. Gastric Cancer. 2023 Mar;26(2):203-19.

[6] Pun C, Luu S, Swallow C, Kirsch R, Conner JR. Prognostic significance of tumour budding and desmoplastic reaction in intestinal-type gastric adenocarcinoma. International journal of surgical pathology. 2023 Sep;31(6):957-66.

[7] Oliveira C, Seruca R, Carneiro F. Hereditary gastric cancer. Best practice & research Clinical gastroenterology. 2009 Apr 1;23(2):147-57.

[8] Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer letters. 2014 Apr 10;345(2):196-202.

[9] D'Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. Advances in nutrition and cancer. 2014:83-95.

[10] van der Sluis L, van Dieren JM, van der Post RS, Bisseling TM. Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review. Hereditary Cancer in Clinical Practice. 2024 Oct 8;22(1):21.

[11] Crew KD, Neugut AI. Epidemiology of gastric cancer. World journal of gastroenterology: WJG. 2006 Jan 1;12(3):354.

[12] Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Official journal of the American College of Gastroenterology| ACG. 2013 Jan 1;108(1):18-37.

[13] Seo N, Lim JS, Cho A. Radiologic Diagnosis (CT, MRI, & PET-CT). Surgery for Gastric Cancer. 2019:67-86.

[14] Christodoulidis G, Koumarelas KE, Kouliou MN, Samara M, Thodou E, Zacharoulis D. The Genomic Signatures of *Linitis Plastica* Signal the Entrance into a New Era: Novel Approaches for Diagnosis and Treatment. International Journal of Molecular Sciences. 2023 Sep 28;24(19):14680.

[15] Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. *Linitis Plastica*: a distinct type of gastric cancer. Journal of Gastrointestinal Surgery. 2020 May 1;24(5):1018-25.

[16] Gajardo JA, Arriagada FJ, Muñoz FD, Veloso FA, Pacheco FA, Molina HE, Schaub TP, Torres OA. Subtotal versus total gastrectomy for distal diffuse-type gastric cancer. Surgical Endoscopy. 2024 Dec;38(12):7588-95.

[17] Japanese Gastric Cancer Association jgca@ koto. kpu-m. ac. jp. Japanese gastric cancer treatment guidelines 2021. Gastric Cancer. 2023 Jan;26(1):1-25.

[18] Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA. Palliative care for advanced gastric cancer. Expert review of anticancer therapy. 2020 Jul 2;20(7):575-80.

[19] Li X, Xu J, Xie J, Yang W. Research progress in targeted therapy and immunotherapy for gastric cancer. Chinese Medical Journal. 2022 Jun 5;135(11):1299-313.

[20] Mastoraki A, Papanikolaou IS, Sakorafas G, Safioleas M. Facing the challenge of managing *Linitis Plastica*--review of the literature. Hepatogastroenterology. 2009 Nov 1;56(96):1773-8.

[21] Christodoulidis G, Agko SE, Koumarelas KE, Kouliou MN. Therapeutic strategies and prognostic challenges in *Linitis Plastica*. World Journal of Experimental Medicine. 2025 Mar 20;15(1).

[22] Högner A, Moehler M. Immunotherapy in gastric cancer. Current oncology. 2022 Mar 2;29(3):1559-74.